Houston, Texas — (March 4, 2026) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutical company developing potentially life-changing technologies for patients that require stem cell or bone marrow transplantation announced today the appointment of Lisa Bollinger, MD as an advisor to the Company. She will provide strategic leadership relating to FDA strategy and regulatory filings.
Lisa Bollinger, M.D. is an advisor to GreenJay, providing expertise in regulatory filings, regulatory strategy and pharmacovigilance. She currently serves as the Chief Medical Officer for Polaryx Therapeutics, a clinical stage biotech and on the Board of Directors for Apogee Therapeutics. Dr. Bollinger’s major areas of focus include, but are not limited to: Pediatric drug development, rare disease drug development, general medicine drug development (Cardiovascular, immunology, metabolic, nephrology, neurology, bone, pulmonary, dermatology). Dr. Bollinger also has experience in pediatric oncology, FDA Advisory Committee Meetings, biosimilars, regulatory inspections, and business
development (due diligence).
Dr. Bollinger is a pediatrician with 20 years of practice experience who began regulatory work at the US Food and Drug Administration (US FDA) in the Division of Dermatologic and Dental Drug Products. During this time, Dr. Bollinger continued to deliver primary care at Walter Reed Military Medical Center in Bethesda Maryland. She was in senior leadership at the FDA where she led pediatric drug development – establishing policies and then implementing them across both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). After the FDA, Dr. Bollinger spent time at Amgen (Regulatory Affairs, Regulatory CMC, Pharmacovigilance), and
three years at Merck (Regulatory Affairs), working cross functionally to bring important therapies to patients. Dr. Bollinger provided consultation for many companies before deciding to join Polaryx Therapeutics as the Chief Medical Officer. She also serves on the Board of Directors for Apogee Therapeutics and advisor for several other companies.
With a broad background across both government and private industry, Dr. Bollinger has experience with high level strategy as well as the hands-on work needed for regulatory interactions, and provides insights that comes from working at the FDA, and in industry across different aspects of drug development. “Dr. Bollinger’s extensive experience with the FDA, large pharma, biotech and as a practicing physician bolsters our team with her skill set, ,” said Michael T. Redman, President & Chief Executive Officer of GreenJay . “We look forward to her contributions as GreenJay prepares to submit for FDA approval.”
GreenJay completed its Series A financing in 2025 and is preparing necessary documentation to submit
for FDA marketing approval. The lead product in development is Bulanta TM , for the treatment of Chronic
Myeloid Leukemia (CML) and other blood cancers and disorders.
About GreenJay
GreenJay Therapeutics, Inc. is a drug formulation company focused on developing drug products with greater drug solubility, improved safety profiles and greater efficacy. The Company’s lead product candidate, BULANTA (IV busulfan), is being developed as an alternative to other IV formulations of busulfan that contain the toxic DMA solvent. BULANTA is in late-stage development for treatment as a conditioning agent for stem cell transplantation. For more information, please visit the Company’s web site at www.greenjaytherapeutics.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of GreenJay’s product candidates, alone and in combination with other therapies, on leukemia and other blood diseases, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of BULANTA and our other potential product candidates including whether we receive fast track or similar regulatory designations; and costs associated with developing our product candidates.
All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
GreenJay Therapeutics, Inc.
mredman@greenjaytherapeutics.com